Healthcare entity

Roche

Company

Sentiment skews more negative than the wider beat, at 40% negative against 26% across all 632 Healthcare stories in the same window. That works out to roughly 0.3 stories per week across a 133-day span. At 6.2, the average consequence score sits above the same-window beat average of 6.1.

Last mentioned: Jul 15, 2026

Entity pulse

Recent coverage · Roche

5 stories
6.2 avg impact
0% positive
40% negative

Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 40 percentage points.

  • 60% neutral
  • 40% negative

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about Roche

Sentiment skews more negative than the wider beat, at 40% negative against 26% across all 632 Healthcare stories in the same window. That works out to roughly 0.3 stories per week across a 133-day span. At 6.2, the average consequence score sits above the same-window beat average of 6.1. Of the tracked stories, 1 of 5 also mention Abbott Laboratories, the most common co-covered peer. Source depth averages 4.2 original sources per story, versus 3.8 across the same-window beat baseline. market-trends accounts for 2 of the 5 tracked stories, while 2 other categories carry the remainder. This profile follows 5 Healthcare stories mentioning Roche across the period from March 5, 2026 to July 15, 2026.

Stories tracked
5
Per week
0.3
Negative
40%
Sources per story
4.2

Computed from the 5 stories linked to this entity, with beat comparisons drawn from all 632 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering Roche. Shared-story counts are live from our verified record — not editorial picks.

Timeline

  1. 79th World Health Assembly

    Target deadline for the conclusion of negotiations on a legally binding global pandemic agreement.

  2. Trial Failure Announced

    Roche confirms the oral SERD candidate failed to meet primary endpoints; shares dip immediately.

  3. Roche Africa Press Day

    Policymakers and scientists meet in Kenya to discuss the transition of labs from emergency assets to essential infrastructure.

  4. Phase II Data Review

    Earlier data had suggested potential efficacy, leading to high investor expectations for the Phase III results.

  5. 78th World Health Assembly

    Adoption of the global pandemic preparedness resolution and initial framework for the PABS system.

  6. Combination Trials Launch

    Roche expanded the program to include combination therapies with CDK4/6 inhibitors.

Stories mentioning Roche 5

Roche is linked from 5 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.